Healthcare / Drug Manufacturers - Specialty & GenericLSE
$1.03
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-340829.00 · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$24M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-34.9%
↓Gross Margin
41.2%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+44.7%
FCF CAGR
—
FCF margin
-26.4%
FCF / Net income
0.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.3M · net income $-452720.0 · FCF $-340829.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.3M | $1.3M | $801964.00 | $389916.00 | $426168.00 |
| Net Income | $-452720.00 | $-452720.00 | $-586243.00 | $-385241.00 | $-224250.00 |
| EBITDA | $-451971.00 | $-451971.00 | $-603592.00 | $-420927.00 | $-299205.00 |
| EPS | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Gross Margin | 41.2% | 41.2% | 35.4% | 75.5% | 89.2% |
| Operating Margin | -35.0% | -35.0% | -75.3% | -108.0% | -70.2% |
| Net Margin | -35.0% | -35.0% | -73.1% | -98.8% | -52.6% |
| Balance Sheet | |||||
| Current Ratio | 3.65 | 3.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-340829.00 | $-340829.00 | $-191498.00 | $-520739.00 | $-213615.00 |
| Returns | |||||
| ROE | -34.9% | -34.9% | -80.9% | -32.4% | -15.0% |
| Valuation | |||||
| P/B | 1813.32 | 1813.32 | 1837.12 | 1351.11 | 1253.57 |
| Growth & Yield | |||||
| Revenue Growth | 61.1% | 61.1% | 105.7% | -8.5% | — |
| EPS Growth | 33.3% | 33.3% | -50.0% | -100.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+110.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → -0.00
Residual
+110.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.